Alkylating agents as leukemogens in multiple myeloma

Richard K. Karchmer, Mammo Amare, William E. Larsen, Alexander G. Mallouk, Glyn G. Caldwell

Cancer · 1974 · 72 citations · 25 references

DOIFull text

Open access

Concepts

Abstract

Five patients in the Kansas City leukemia surveillance program had a history of multiple myeloma prior to the onset of their acute leukemia. If one applies the Kansas City age/sex-specific leukemia rates to an estimated population with multiple myeloma living in the study area during the 7-year collection period, only 0.17 patients would be expected to develop acute leukemia. The five patients presented in this paper represent a significant increase in the observed over the expected incidence. Twenty-six patients have now been reported who developed acute leukemia during treatment for multiple myeloma, and each had received an alkylating agent. These drugs may be direct leukemogens and the risk involved in their use must be recognized.

References

25